News > International

03rd August 2016

PCI Pharma Services Welcomes Two New Business Development Executives to Support its Growing US Market

Leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the appointment of Sue Ritchie and Fred Schulze to its US sales team, with business development responsibility for PCI’s expanding global development and manufacturing capability. Sue and Fred join PCI to develop clients across the full suite of PCI’s drug development services spanning analytical…

21st July 2016

United Life Sciences explores the UK life sciences landscape following the EU Referendum outcome: What’s next for UK life sciences?

The UK has voted to leave the European Union (EU). Although this decision has caused political and economic uncertainty for the country, it also presents a new political context with opportunities for a re-energised vision for the UK life sciences sector. United Life Sciences, formed of BIA, Bionow, BioPartner UK, One Nucleus and MediWales, will…

21st July 2016

Geldards: Brexit – Business as usual?

It’s been almost a month now since the UK voted to leave the EU. However, the political turmoil that has followed has meant that we are no further forward in terms of knowing when the UK will give notice to the European Council of its intention to withdraw from the EU, how that will be…

14th July 2016

TrakCel joins Smart Cell Processing Project Ecosystem to standardise cell therapy processing and delivery

TrakCel, a leading provider of traceability technology to aid in the delivery of regenerative therapies, has announced that it has joined the Smart Cell Processing Project Ecosystem, a joint program with academic and industrial partners. Tokyo Electron established the Stem Cell Technology Centre and is working with over 15 partners to establish and standardise smart cell…

11th July 2016

BBI Solutions launches new SCIPAC Clinical Specimen Panels, speeding up assay development for infectious diseases

BBI Solutions (BBI) today announced the launch of SCIPAC Clinical Specimen Panels. SCIPAC are quantitative panels of clinical specimen, collected from multiple donors of known genotype. Panels currently available from BBI include the SCIPAC range of Hepatitis, HIV and Syphilis. Adding to BBI’s extensive biobank portfolio, the panels provide a quantity of trusted patient samples to…

11th July 2016

Grant Thornton: UK votes to leave the EU – advice and scenario planning

The people of the UK have taken the decision to leave the European Union. What happens next – and the implications for businesses and organisations in the UK – is less clear. It is now up to the UK Government to decide on what economic relationship it would seek to replace our current EU membership. To…

11th July 2016

Finance Wales’ statement on Brexit

Following last week’s EU referendum vote, Finance Wales has clarified its position for all partners and stakeholders. The Wales Business Fund is progressing as planned and Finance Wales is working with WEFO on the official launch of the £136 million fund this September. Finance Wales currently manages an additional 10 investment funds for SMEs, with funds in…

11th July 2016

Made in the UK export award winner, BBI Solutions, is attending AACC

BBI Solutions (BBI), recent winners of the Made in the UK Export Award, will be attending the AACC Clinical Lab Expo in Philadelphia next month. BBI, a leading manufacturer of raw materials and finished test platforms for the in-vitro diagnostics market, has been recognised for its exporting achievements over the past 25 years, winning the…

05th July 2016

ABHI: Brexit Update

Given the rapid developments and continued uncertainty following the recent EU referendum, ABHI has circulated an update to shape both the long-term outlook for the medical technology industry and address near-term business needs. The sector was represented at Tuesday 28th June’s business leader round table hosted by Sajid Javid MP, the Secretary of State for Business, Innovation and Skills….

24th June 2016

Orphan Drug Designation granted to Neem Biotech’s lead drug candidate for the treatment of Pseudomonas aeruginosa lung infections in CF patients

Neem Biotech’s lead candidate NX-AS-401 has recently received Orphan Drug Designation from the United States FDA for treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. This is a significant boost for the ongoing development of Neem’s flagship candidate drug substance. The outcome of an application for Orphan Drug Designation from the European Medicine…